

# Result of the non-invasive prenatal examination

Fax: 075319769460

LifeCodexx AG | Line-Eid-Straße 3 | DE-78467 Konstanz

Max Musterarzt  
Musterpraxis  
Line-Eid-Straße 3  
Konstanz

Title, last name, first name of patient

Musterfrau, Martina

Singleton or multiple pregnancy

Singleton pregnancy

Date of birth

1974-06-28\*

Test option

Test option 3

Sample received on

2013-01-23\*

Examination material

EDTA blood

Bar code no.

00103541

Lab ID

LCD01673

QC

approved

cffDNA content

12 %

| Chromosome      | Result                             | Interpretation   |
|-----------------|------------------------------------|--|
| Chromosome 21   | <b>outside of the normal range</b> | Evidence of fetal trisomy 21                                 |
| Chromosome 18   | within the normal range            | No evidence of fetal trisomy 18                              |
| Chromosome 13   | within the normal range            | No evidence of fetal trisomy 13                              |
| Sex chromosomes | within the normal range            | No evidence of Turner, Triple-X, Klinefelter or XYY syndrome |

Based on this positive test result, we wish to highlight the need for genetic counseling and its significance with regard to the implications for the patient who underwent the examination and her family. According to recommendations from international professional associations, further medical clarification, usually in the form of invasive diagnostics, is urgently recommended to validate the test result. We request a response in the event of inconsistent results.

Random massively parallel sequencing (rMPS) (or: next generation sequencing, NGS) was the method applied for this analysis.

## Fetal sex

female

When informing the pregnant patient of the fetal sex, please ensure that the national regulations applicable in each case are complied with.

**Test method and analysis result:** The PrenaTest® for the determination of the chromosomal disorders tested is based on the latest next generation sequencing (NGS) and PCR technologies using CE-marked software and CE-marked in-vitro diagnostic test systems [according to the intended purpose and declaration of conformity]. During use of the PrenaTest® in clinical practice, 100% accuracy cannot be expected. In general, no statements regarding structural chromosomal changes, mosaics or polyploidy can be made with the PrenaTest®. More information on the appraisal of results (sensitivity/specificity) and accuracy of the PrenaTest®, the limits of the examination as well as fetal sex determination can be found at [www.lifecodexx.com](http://www.lifecodexx.com).

Konstanz, 2018-11-29\*

Validation performed by  
Dr. M. Mustermann (initial validation) and J. Mustermann, M.Sc. Bioinformatics (final validation)

This results report was electronically generated and is valid without a signature.